多发性骨髓瘤首次挽救治疗后持续使用泊马度胺联合地塞米松直至疾病进展
在IFM 2009试验及IFM 2013-01 2期试验中首次复发的骨髓瘤患者,接受4周期泊马度胺+环磷酰胺+地塞米松(PCD)挽救治疗(移植者加2周期PCD巩固,未移植者共5周期PCD),随后所有患者接受泊马度胺联合地塞米松维持治疗(28天周期:泊马度胺4 mg/d第1-21天,地塞米松20 mg每周一次)直至进展。100例中75例进入该治疗,中位随访73个月,中位治疗时长23.7个月,三分之一患者反应改善,中位无进展生存33.2个月,中位总生存未达到。
要点
- 首次复发骨髓瘤患者中75/100例进入泊马度胺联合地塞米松维持治疗,中位随访73个月。
- 中位治疗时长23.7个月,中位无进展生存33.2个月,中位总生存未达到。
- 三分之一患者反应改善:11%达非常好的部分缓解,19%达完全缓解,4%达严格完全缓解。
核心结论
- 长期给予泊马度胺联合地塞米松是可行的,且三分之一患者反应得到改善。
研究设计与样本
- 骨髓瘤患者来自IFM 2009试验首次复发者及随后IFM 2013-01 2期试验,接受4周期PCD挽救治疗,移植者加2周期PCD巩固,未移植者共5周期PCD,所有患者接受泊马度胺联合地塞米松维持治疗。
- 维持方案为28天周期:泊马度胺4 mg每日第1-21天,地塞米松20 mg每周一次,直至疾病进展。
- 主要终点为治疗反应改善;100例中75例进入该治疗,中位随访73个月。
主要发现
- 中位治疗时长23.7个月。
- 三分之一患者自治疗开始反应改善:11%达非常好的部分缓解,19%达完全缓解,4%达严格完全缓解。
- 中位无进展生存33.2个月,中位总生存未达到。
- 75例中泊马度胺停药原因:疾病进展54%,不良事件30%,研究者判断11%,撤回知情同意5%。
- 3/4级血液学不良事件包括中性粒细胞减少51%和淋巴细胞减少35%;3/4级药物相关非血液学不良事件(>5%)包括感染13%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide maintenance in myeloma is well established. Nevertheless, pomalidomide could provide an alternative. Myeloma patients in first relapse, initially treated in the Intergroupe Francophone du Myélome (IFM) 2009 trial, and subsequently in the IFM 2013-01 phase 2 trial, received four cycles of salvage therapy with pomalidomide plus cyclophosphamide plus dexamethasone (PCD) with transplantation plus 2 PCD consolidation or without transplantation but with 5 PCD and for all patients pomalidomide plus dexamethasone maintenance therapy. This consisted of 28-day cycles of pomalidomide 4 mg daily on days 1-21 and dexamethasone 20 mg weekly until progression. The primary endpoint was an improved response to treatment. A total of 75/100 patients reached therapy. The median follow-up time was 73 months. The median duration of treatment was 23.7 months. One third of patients improved their response from the initiation of treatment: 11%, 19% and 4% to a very good partial response, complete response or stringent complete response respectively. The median progression-free survival time was 33.2 months and the median overall survival time was not reached. Among the 75 patients, the reasons for pomalidomide discontinuation were progressive disease (54%), adverse events (AEs) (30%), investigator discretion (11%) and consent withdrawal (5%). Grade (G) 3/4 haematological AEs included neutropenia (51%) and lymphopenia (35%); G3/4 drug-related non-haematological AEs (>5%) comprised 13% infections. Long-term administration of pomalidomide and dexamethasone is feasible and one third of the patients improved their response.
引用
- Garderet L, Kuhnowski F, Berge B, et al. Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. Br J Haematol. 2023. PMID: 36974007. doi:10.1111/bjh.18772
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。